Genzyme acquires rights to three drugs from Bayer HealthCare
In an agreement funded solely through the achievement of milestones and royalties, Bayer HealthCare has licensed Genzyme exclusive global development and commercialization rights to Campath/MabCampath (alemtuzumab) for multiple sclerosis and B-cell chronic lymphocytic leukemia (CLL), and exclusive worldwide rights to present and future indications of the cancer drugs Fludara (fludarabine) and Leukine (sargramostim).
- Large Molecule
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.